Anzeige
Mehr »
Login
Mittwoch, 13.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Wir entschlüsseln die 55 $ pro Aktie Clean-Energy-Chance für SIE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
1.403 Leser
Artikel bewerten:
(2)

Tenon Medical, Inc.: Tenon Medical to Showcase Company's Catamaran SI Joint Fusion System at the 2022 North American Spine Society 37th Annual Meeting

Finanznachrichten News

~Company to launch Catamaran nationally at NASS with technical exhibit and interactive surgeon training sessions~

~ Outcomes from a single center experience with the Catamaran to be presented at Innovative Technology Session, October 13th ~

LOS GATOS, CA / ACCESSWIRE / October 12, 2022 / Tenon Medical, Inc. ("Tenon" or the "Company") (NASDQ:TNON), a company transforming care for patients suffering with certain sacroiliac disorders, today announced the Company's attendance and planned activities at the37th Annual Meeting of the North American Spine Society (NASS), being held in Chicago from October 12 -15, 2022. The NASS meeting is attended by over 3,500 spine specialists-orthopedic surgeons, neurosurgeons, radiologists, and other health care providers.

As recently disclosed, Tenon has terminated its legacy distribution agreement with its former distribution partner, SpineSource, and has assumed control of all commercial distribution & sales activities of the Catamaran SI Joint Fusion System ("Catamaran"). Tenon has begun developing its own commercial infrastructure and sales management team that will partner with key independent spine distributors throughout the country who are motivated to represent the Company's Catamaran. The Company is using the NASS meeting as the national launch event for the Catamaran, which is the only single, titanium fixation device that is implanted from an inferior-posterior approach and transfixes the SI Joint along its longitudinal axis to treat conditions such as SI joint disruption and degenerative sacroiliitis.

The Company will have an interactive hands-on technical exhibit (#2134) where health care providers attending the meeting can learn more about the Catamaran and its novel inferior-posterior approach. Throughout the meeting the Tenon exhibit booth will also host Catamaran "Meet the Expert" sessions where Drs Mark H. Stouffer, MD (orthopedic spine surgeon, St. George, UT) and Scott C. Kutz, MD (Neurosurgeon, Plano, TX.) will share their Catamaran clinical experience, patient selection criteria and associated clinical outcomes with attendees visiting the exhibit.

Tenon Medical, Inc., Wednesday, October 12, 2022, Press release picture

On Thursday October 13th, Dr Michael Chaparro, MD, from Loxahatchee, FL will present his single center Catamaran experience. The presentation, entitled "Sacroiliac Fusion via an Inferior-Posterior Approach with a Novel Single SI Joint Fixation Device" will take place in the Red Theater in McCormick Place at 1:30pm. The presentation will introduce the Catamaran technology as an innovative option to treat certain SI Joint disorders, its associated surgical technique and Dr Chaparro's clinical outcomes reported out to 12 months.

Tenon Medical, Inc., Wednesday, October 12, 2022, Press release picture

Tenon will also host multiple Catamaran hands-on technical workshops for invited physicians interested in learning more about how the implant transfixes and stabilizes the SI joint, as well as why the inferior-posterior approach is an optimal entry point. Utilizing the Company's proprietary synthetic SI Joint training model, surgeons attending the workshop will simulate implanting the Catamaran Fixation Device under fluoroscopy using the systems innovative, yet simple instrumentation set and a defined 2D fluro-imaging sequence.

"The entire Tenon team is very excited about launching the Catamaran SI Joint Fusion System at a prestigious scientific conference like NASS." states Steven M. Foster, President and CEO of Tenon. "Catamaran offers a distinct inferior-posterior approach and transfixing implant for physicians seeking better options for their patients suffering from SI joint related issues. Our NASS activities will be focused on showcasing this unique story and providing hands-on workshops focused on Catamaran. The introduction of this single, robust titanium implant solution is a critical first step in building commercial momentum for Tenon."

About Tenon Medical, Inc.

Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI joint along its longitudinal axis. With an entry that mimics SI joint injection, the surgical approach is direct to the joint and inferior to the wide and variable dorsal recess. The angle and trajectory of the Inferior-Posterior approach is designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Tenon is preparing a national launch of this system to address the greatly underserved market opportunity that exists in this space. For more information, please visit https://www.tenonmed.com/.

The Tenon Medical logo and Tenon Medical, are registered trademarks of Tenon Medical, Inc. Catamaran is a trademark of Tenon Medical, Inc.

Safe Harbor

This press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our Registration Statement on Form S-1 on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled "Risk Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.

IR Contact:

Shannon Devine: 203-741-8811
MZ North America
tenon@mzgroup.us

SOURCE: Tenon Medical, Inc.



View source version on accesswire.com:
https://www.accesswire.com/719942/Tenon-Medical-to-Showcase-Companys-CatamaranTM-SI-Joint-Fusion-System-at-the-2022-North-American-Spine-Society-37th-Annual-Meeting

© 2022 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.